GE HealthCare Introduces Pristina Via Mammography System at RSNA
The new mammography system reportedly offers features that promote workflow efficiency as well as patient comfort.
Emphasizing enhanced workflow efficiency for mammography exams, GE HealthCare will unveil the Pristina Via mammography platform at the Radiological Society of North America (RSNA) conference.
In addition to offering zero-click acquisition to facilitate streamlined workflow, the Pristina Via mammography system incorporates prior image comparison, irrespective of mammography vendor, to aid in mammography assessments, according to GE HealthCare.
The Pristina Via mammography system, which will be unveiled at the RSNA conference, offers image to image cycle time for digital breast tomosynthesis (DBT) that is up to twice as fast as other mammography platforms, according to GE HealthCare. (Image courtesy of GE HealthCare.)
The company adds that the Pristina Via system offers image to image cycle time for digital breast tomosynthesis (DBT) that is up to twice as fast as other mammography platforms, as well as the lowest radiation dose for all breast thicknesses.
“Simplifying, automating, and streamlining the mammography exam to improve in-room workflows is critical to driving patient compliance and access to screening,” said John Simon, M.D., the CEO of SimonMed. “The enhancements offered by Pristina Via are part of our mission of making advanced technology accessible.”
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
